The B cell-activating factor (BAFF) is critical for B cell development and humoral immunity in mice and humans. While the role of BAFF in B cells has been widely described, its role in innate immunity remains unknown. Using BAFF receptor (BAFFR)-deficient mice, we characterized BAFFR-related innate and adaptive immune functions following infection with vesicular stomatitis virus (VSV) and lymphocytic choriomeningitis virus (LCMV). We identified a critical role for BAFFR signaling in the generation and maintenance of the CD169 ؉ macrophage compartment. Consequently, Baffr ؊/؊ mice exhibited limited induction of innate type I interferon production after viral infection. Lack of BAFFR signaling reduced virus amplification and presentation following viral infection, resulting in highly reduced antiviral adaptive immune responses. As a consequence, BAFFR-deficient mice showed exacerbated and fatal disease after viral infection. Mechanistically, transient lack of B cells in Baffr ؊/؊ animals resulted in limited lymphotoxin expression, which is critical for maintenance of CD169 ؉ cells. In conclusion, BAFFR signaling affects both innate and adaptive immune activation during viral infections.
T he B cell-activating factor (BAFF) receptor (BAFFR) is critical for B cell development (1, 2) . Patients lacking the BAFFR have been identified within cohorts with common variable immunodeficiency, the most prevalent symptomatic primary immunodeficiency in adult patients. BAFFR-deficient humans exhibit severe B cell lymphopenia and impaired immunoglobulin production (3) . Similarly, the lack of BAFF signaling in Baffr Ϫ/Ϫ mice is also associated with severe B cell lymphopenia (4) . BAFF binds to three receptors, the BAFFR, transmembrane activator and CAML interactor (TACI), and B cell maturation antigen (BCMA) (5) . While TACI and BCMA engage both BAFF and a proliferation-inducing ligand (APRIL), BAFFR binds BAFF exclusively. The BAFF-BAFFR association leads to recruitment and degradation of TRAF3 (6) . TRAF3 negatively regulates NF-B-inducing kinase (NIK), the upstream kinase for NF-B2 activation (7) . In the presence of BAFF, degradation of TRAF3 leads to stabilization of NIK and activation of NF-B2, which triggers B cell survival (8) (9) (10) (11) .
Furthermore, BAFF triggers activation of Akt signaling pathways, which increase the metabolic activity of B cells (12) . Additionally, BAFF transmits survival signals via Erk activation, which triggers phosphorylation and degradation of the proapoptotic molecule Bim (13) (14) (15) . Together, these signaling pathways promote BAFFmediated survival of B cells. Whether innate immunity may be abnormal in Baffr Ϫ/Ϫ mice has not yet been investigated. Successful defense against viral infections relies on effective innate and adaptive immunity. During infection, viral particles are captured in secondary lymphoid organs, such as the lymph node or the spleen (16) . In mice, macrophages in the marginal sinus in the splenic white pulp or macrophages located in the subcapsular space of the lymph node filter pathogens from the blood and the lymph, respectively (16) (17) (18) . Metallophilic macrophages and subcapsular sinus macrophages are characterized by expression of the C-type lectin CD169 (Siglec-1) (19) . CD169 ϩ cells are critical for innate cytokine production and viral antigen presentation to B cells and represent an important link between innate and adaptive immunity (18) . In particular, Usp18-driven suppression of antiviral type I interferon signaling allows viral replication to occur in CD169 ϩ cells in close proximity to marginal-zone B cells (20, 21) . Consequently, large quantities of viral antigen are made available in order to induce rapid and robust adaptive immunity (22) (23) (24) (25) . The rapid induction of adaptive immune responses as a result of early viral replication in the spleen guarantees virus elimination and survival of the virus-infected host (20, 21) .
B cells are important for the generation of the splenic architecture, including maintenance of the marginal zone (26, 27) . Following a recent report indicating that BAFF is produced by neutrophils in the marginal zone of the spleen (28), we chose to investigate the impact of BAFFR signaling on innate immune responses. We found that absence of BAFFR resulted in reduced lymphotoxin expression, decreased presence of CD169 ϩ cells, delayed and impaired innate and adaptive immune activation, and, consequently, promotion of fatal disease development after viral infection.
MATERIALS AND METHODS
Mice. Mice were infected intravenously with vesicular stomatitis virus (VSV) or lymphocytic choriomeningitis virus (LCMV) at the indicated doses. Baffr Ϫ/Ϫ mice were bred on a C57BL/6 genetic background (4). CD45.1 ϩ mice were purchased from Jackson Laboratory. Ltb fl/fl ϫ CD19-Cre ϩ and Ifnar1 Ϫ/Ϫ mice were previously described (29, 30) . All experiments were performed in single ventilated cages. During survival experiments, the health status of the mice was checked twice daily. Upon the appearance of clinical signs of VSV replication in the central nervous system (CNS), such as paralysis, mice were removed from the experiment. Animal experiments were carried out with the authorization of the Veterinäramt of Nordrhein Westfalen, Recklinghausen, Germany, in accordance with the German law for animal protection and the institutional guidelines of the Ontario Cancer Institute.
Viruses. VSV, Indiana strain (VSV-IND, Mudd-Summers isolate), was originally obtained from D. Kolakofsky (University of Geneva, Geneva, Switzerland). The virus was propagated on BHK-21 cells at a multiplicity of infection (MOI) of 0.01 and was then plaqued onto Vero cells. LCMV was used and virus titers were determined as previously described (21) . Viruses were administered to mice through intravenous injection.
Poly(I·C) and recombinant interferon. Poly(I·C) (GE Healthcare Life Sciences) and mouse recombinant interferon alpha (IFN-␣) A (PBL Biosciences) were administered to mice through intravenous injection at the indicated doses.
Neutralizing antibodies were determined by a plaque reduction neutralization test (PRNT) as previously described (21) . Serum was prediluted (1:40) , and the complement system was inactivated (56°C for 30 min). The serum was titrated 1:2 over 12 steps and incubated with 1,000 PFU of VSV. After 90 min of incubation, the virus-serum mixture was plaqued on Vero cells. An overlay was added after 1 h. Plaques were counted 24 h later by crystal violet staining. The cutoff was 50% reduction of plaques compared to serum-free controls.
ELISA. Interferon alpha enzyme-linked immunosorbent assay (ELISA) (PBL Biosciences) was performed as instructed by the manufacturer.
Purification of B cells. For B cell purification, single-cell suspensions of splenocytes were enriched following the manufacturer's instructions with a CD45R (B220) MicroBeads mouse kit (Miltenyi).
RT-PCR analyses. RNA purification and real-time (RT)-PCR analyses were performed as previously described according to the manufacturer's instructions (Qiagen) (31) . Gene expression of Isg15, Mx1, Ifit2, Lta, Ltb, and Gapdh was performed using kits from Applied Biosystems. For analysis, the expression levels of all target genes were normalized to GAPDH (glyceraldehyde-3-phosphate dehydrogenase) expression levels (⌬C T ).
Gene expression values were then calculated based on the ⌬⌬C T method relative to naive wild-type (WT) controls. Relative quantities (RQ) were determined using the following equation: RQ ϭ 2 Ϫ⌬⌬CT . Histology. Histological analyses were performed on snap-frozen tissue as described previously by using anti-VSV-G monoclonal antibody (clone Vi10) (21) . CD90.2, CD4, CD8, and B220 antibodies were purchased from eBioscience (San Diego, CA). CD169 (clone MOMA-1) antibody was obtained from Abcam (Cambridge, MA). Hematoxylin and eosin (H&E) staining was described previously (32) .
Flow cytometry. Flow cytometry analyses were performed as previously described for LCMV tetramer staining and intracellular-cytokine staining (33) . Different spleen immune populations were identified using anti-B220 (RA3-6B2), anti-major histocompatibility complex class II (MHC-II) (M5/114.15.2), anti-CD11c (N418), anti-GR-1 (RB6-8C5), anti-F4/80 (BM8), anti-CD3 (145-2C11), anti-CD8 (52-6.7), and anti-CD4 (GK1.5) antibodies (clone). Stem cell analyses were performed as previously described (34) . The lineage (Lin) antibody mixture used for progenitor analysis contained CD3, CD11b (M1/70), Ly6C, Ter119 (TER-119), CD19, CD11c, MHC-II, interleukin 7 receptor (IL-7R) (A7R34), and NK1.1. Common myeloid progenitors (CMP) and granulocyte and macrophage progenitors (GMP) were determined using anti-CD34 (RAM34), anti-CD16/32 (93), anti-Sca1 (D7), and anti-CD117 (2B8) antibodies. All antibodies were obtained from eBioscience (San Diego, CA), except anti-CD169 (3D6.112), which was obtained from AbD Serotec (Dusseldorf, Germany).
Statistical analysis. Data are expressed as means and standard errors of the mean (SEM). Student's t test was used to detect statistically significant differences between two groups. Significant differences between several groups were detected by one-way analysis of variance (ANOVA) with Bonferroni or Dunnett post hoc tests or as mentioned specifically in the figure legends. The level of statistical significance was set at a P value of Ͻ0.05.
RESULTS

BAFFR is critical in overcoming viral infection.
Murine BAFFR deficiency resulted in severe B cell lymphopenia but did not have a major impact on T cell, dendritic cell, or neutrophil numbers ( Fig.  1A and B). As expected, Baffr Ϫ/Ϫ mice exhibited delayed virusneutralizing antibody production after infection with the cytolytic VSV (Fig. 1C ). Consistent with a requirement for rapid neutralizing antibody formation for elimination of VSV (21), Baffr Ϫ/Ϫ mice succumbed to VSV infection, while WT animals overcame the infection (Fig. 1D ). When neuronal tissue was harvested from the sick animals (days 7 to 10), the presence of VSV could be detected (data not shown). These data suggest that absence of BAFFR resulted in fatal disease development during infection with VSV.
BAFFR mediates enforced viral replication during viral infection. Despite detection of VSV replication in the CNS in the later phase of infection, VSV titers were below the detection limit in spleen tissues of Baffr Ϫ/Ϫ animals 8 h and 24 h after infection with VSV, while virus was readily detectable in WT controls ( Fig.  2A) . Overcoming VSV infection is not only dependent on production of neutralizing antibodies, but also on innate type I interferon production (30, 35, 36) . Consistent with decreased replication of VSV in spleen tissue, Baffr Ϫ/Ϫ mice had reduced type I interferon levels in the serum compared to infected WT mice (Fig. 2B) . Moreover, the increase of interferon-regulated genes (IRGs), such as Isg15, Mx1, and Ifit2, 24 h after VSV infection was reduced in brain tissue harvested from BAFFR-deficient animals compared to their corresponding controls (Fig. 2C) . However, competent production of type I interferon was detectable in Baffr Ϫ/Ϫ mice following injection of the Toll-like receptor 3 (TLR3) agonist poly(I·C) in vivo (Fig. 2D) . Furthermore, IRG expression levels in the brain tissues from Baffr Ϫ/Ϫ mice and their WT controls following treatment with poly(I·C) were similar (Fig. 2E) . This indicates that the capacity to induce type I interferon was normal in Baffr Ϫ/Ϫ mice. Moreover, when animals were treated with mouse recombinant IFN-␣, similar brain IRG expression levels were observed in BAFFR-deficient and WT mice (Fig. 2E) . Collectively, reduced type I interferon levels in Baffr Ϫ/Ϫ mice following virus infection was likely explainable by a different mechanism than defective pathogen recognition receptor (PRR) signaling.
BAFF signaling is required for maintenance of metallophilic macrophages in the spleen. We have recently demonstrated that early virus replication in the spleen depends on CD169 ϩ metallophilic macrophages and is triggered by Usp18-mediated resistance to type I interferon in these cells (21) . In mice, CD169 ϩ cells in the spleen are in direct contact with the bloodstream and remove virus particles and apoptotic cells from circulation (21, 37) . Lack of CD169 ϩ macrophages blocks virus replication early after infection, causing limited antigen amplification and reduced virus-induced immune activation (21, 38 (Fig. 3A) . However, CD169 ϩ metallophilic macrophages, which have a critical role during early viral replication (21), were highly reduced in spleen tissue of Baffr Ϫ/Ϫ mice compared to WT animals (Fig. 3B) , while red-pulp macrophages were present at similar frequencies (Fig. 3C) . Taken together, the data show that BAFFR appears to be required for maintenance of CD169 ϩ cells. Next, we investigated the presence of CD169 ϩ cells following infection. CD169
ϩ cells are present at reduced numbers in BAFFR-deficient animals, but a residual population is still detectable in the naive state ( Fig. 3D and E) . However, shortly after infection with VSV, CD169 ϩ cells rapidly disappear in Baffr Ϫ/Ϫ mice, in contrast to WT animals (Fig. 3D) . As a consequence of reduced CD169 ϩ macrophages, VSV protein (detected by the VSV-specific monoclonal antibody Vi10) was reduced in Baffr Ϫ/Ϫ mice in spleen sections following VSV infection, while it was readily detectable in spleen sections from WT animals (Fig. 3E) . Next, we wondered whether type I interferon directly affected CD169 ϩ cell survival. However, the distributions of CD169 ϩ cells in spleen tissues harvested from Ifnar1 Ϫ/Ϫ mice and WT animals were similar (Fig. 4) . Taken together, these data indicate that lack of BAFFR expression is associated with a decreased presence of splenic 
CD169
ϩ cells after virus infection, which consequently diminishes early viral replication.
BAFFR deficiency results in reduced B cell-mediated maintenance of CD169
؉ cells. Next, we addressed whether the reduction of CD169 ϩ cells in Baffr Ϫ/Ϫ mice occurred due to severe B cell lymphopenia (39, 40 of BAFFR-deficient mice that were supplemented with B cells (Fig.  5A) . Furthermore, type I interferon production following VSV infection could be partially rescued by the transfer of WT B cells into Baffr Ϫ/Ϫ mice (Fig. 5B) . Moreover, neutralizing antibody titers of the Baffr Ϫ/Ϫ animals that received WT B cells was increased compared to Baffr Ϫ/Ϫ animals (Fig. 5C) , and the animals could overcome the VSV infection (Fig. 5D ). These data indicate that B cells mediate maintenance of CD169 ϩ cells and consequently contribute to innate immunity during infection.
Lymphotoxin signaling is critical for CD169 ϩ cell development in spleen and lymph node tissues (32, 38, 39, 41) . Moreover, it has been shown that lymphotoxins are derived from B cells, which are important for maintenance of CD169 ϩ cells (29, 39) . Consistently, BAFFR-deficient animals exhibited lower lymphotoxin alpha (Lt␣) and lymphotoxin beta (Lt␤) expression levels than their corresponding controls (Fig. 6A) . These data suggest that impaired B cell numbers in Baffr Ϫ/Ϫ mice may contribute to insufficient lymphotoxin expression to maintain normal levels of CD169 ϩ cells (29, 38, 41, 42) . To investigate the role of lymphotoxin beta during enforced viral replication, we infected Ltb fl/fl ϫ CD19-Cre ϩ animals and compared them to their corresponding controls. As expected, these animals exhibited fewer CD169 ϩ cells than the WT controls (Fig. 6B) (29, 42) . Consistent with previous reports and our data obtained in Baffr Ϫ/Ϫ mice, we observed reduced type I interferon production shortly after infection in Ltb fl/fl ϫ CD19-Cre ϩ mice compared to Ltb fl/fl ϫ CD19-Cre Ϫ animals (Fig. 6C) (39) . Furthermore, low-dose infection resulted in reduced production of neutralizing antibodies (Fig. 6D) . These data indicate that lack of B cells or B cell-derived expression of Lt␤ results in limited innate immune activation and delayed adaptive immune priming.
BAFFR deficiency results in limited innate immune activation following LCMV infection.
To further analyze the importance of BAFFR in viral replication and the induction of antiviral immunity, we examined Baffr Ϫ/Ϫ mice following LCMV infection. Consistent with the VSV infection, we observed reduced LCMV replication in the spleen tissue of Baffr Ϫ/Ϫ mice in comparison to WT controls at 72 h after infection (Fig. 7A) . Furthermore, type I interferon levels were highly reduced in the sera of Baffr Ϫ/Ϫ animals compared to WT controls (Fig. 7B) . Tetramer-positive LCMV-specific T cells were highly reduced following LCMV infection of Baffr Ϫ/Ϫ mice compared to WT mice (Fig. 7C) . Moreover, IFN-␥ production after in vitro restimulation with LCMV peptides was reduced in both CD8 ϩ and CD4 ϩ T cells harvested from Baffr Ϫ/Ϫ mice in comparison to WT controls (Fig. 7D) . When viral titers were determined 20 days after infection, WT animals had eliminated the virus from all organs tested (Fig. 7E) . In sharp contrast, LCMV-infected Baffr Ϫ/Ϫ mice displayed high virus titers in all organs tested (Fig. 7E) . Collectively, these data suggest that the absence of BAFFR signaling causes impaired generation of the marginal-zone compartment and impaired induction of innate and adaptive immune responses during viral infection.
DISCUSSION
In this study, we have identified a critical role for BAFFR in the maintenance of CD169 ϩ macrophages. Baffr Ϫ/Ϫ mice showed limited innate immune activation and reduced adaptive immune priming associated with fatal disease outcome. Mechanistically, impaired B cell development in Baffr Ϫ/Ϫ mice resulted in limited lymphotoxin expression and, likely as a consequence, reduced presence of CD169 ϩ cells. BAFF can be produced by a variety of immune cells, including dendritic cells, macrophages, and neutrophils (5) . Interestingly, a recent report indicated BAFF-producing neutrophils were located in the marginal zone of the spleen (28) . These neutrophil B helper cells contribute to marginal-zone B cell activation and antibody production against pathogens (28) . Based on our results, BAFF production by neutrophil B helper cells, by promoting B cellmediated lymphotoxin production, may also affect CD169 ϩ cell survival and subsequently enforce antigen amplification and presentation. Furthermore, BAFF overexpression has been linked to a variety of autoimmune diseases, such as rheumatoid arthritis, lupus erythematosus, and Sjögren syndrome (5, (43) (44) (45) . A clinically used BAFF-blocking antibody, belimumab, is effective in treating some lupus patients (46) , and potentially, some clinical efficacy of BAFF neutralization in lupus patients may be due to effects on CD169 ϩ macrophages. Viral infections are potent activators of the immune system and can trigger autoimmunity (47) through several mechanisms, including molecular mimicry and bystander activation (48) . Increased BAFF levels may affect not only B cell-mediated autoimmunity, but also B cell-mediated effects on CD169 ϩ macrophages to increase bystander activation. Furthermore, replication of low-affinity antigens in CD169 ϩ macrophages may contribute to development of virus-mediated autoimmunity induced by molecular mimicry (49) . Considering our data, altered BAFF expression levels may lead to increased immune responses during viral infections. These mechanisms could also contribute to induction of autoantibodies observed during viral infections (50, 51) .
As we show here, defects in BAFFR expression may limit innate immunity during infection. This may be triggered by reduced lymphotoxin beta production by B cells, as lack of lymphotoxin beta resulted in reduced presence of CD169 ϩ macrophages (29, 38, 39) . Furthermore, lymphotoxins trigger innate type I interferon production during viral infection (52, 53) . This may be in part triggered by enforced viral replication in CD169 ϩ cells, which is also critical for induction of adaptive immune priming (21, 49) . Considering our data, deletions in BAFFR may not only affect B cell-driven immunity, but also trigger defects in innate immunity. Future studies may analyze the role of BAFFR deficiency during innate immunity in human patients.
In conclusion, we have determined that BAFFR deficiency mediates reduced presence of B cells, impacting the maintenance of CD169 ϩ macrophages and innate immunity.
